• Lien Dejager, Sofie Vandevyver, Ioanna Petta, and Claude Libert.
• Department for Molecular Biomedical Research, Flanders Institute for Biotechnology, B9052 Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, B9052 Ghent, Belgium.
• Cytokine Growth Factor Rev. 2014 Feb 1; 25 (1): 21-33.

AbstractPro-inflammatory cytokines are involved in the pathogenesis of many inflammatory diseases, and the excessive expression of many of them is normally counteracted by glucocorticoids (GCs), which are steroids that bind to the glucocorticoid receptor (GR). Hence, GCs are potent inhibitors of inflammation, and they are widely used to treat inflammatory diseases, such as asthma, rheumatoid arthritis and inflammatory bowel disease. However, despite the success of GC therapy, many patients show some degree of GC unresponsiveness, called GC resistance (GCR). This is a serious problem because it limits the full therapeutic exploitation of the anti-inflammatory power of GCs. Patients with reduced GC responses often have higher cytokine levels, and there is a complex interplay between GCs and cytokines: GCs downregulate pro-inflammatory cytokines while cytokines limit GC action. Treatment of inflammatory diseases with GCs is successful when GCs dominate. But when cytokines overrule the anti-inflammatory actions of GCs, patients become GC insensitive. New insights into the molecular mechanisms of GR-mediated actions and GCR are needed for the design of more effective GC-based therapies. Copyright © 2014. Published by Elsevier Ltd.

27 keywords...

hide…